𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

✍ Scribed by Vermorken, Jan B; Stöhlmacher-Williams, Jan; Davidenko, Irina; Licitra, Lisa; Winquist, Eric; Villanueva, Cristian; Foa, Paolo; Rottey, Sylvie; Skladowski, Krzysztof; Tahara, Makoto; Pai, Vasant R; Faivre, Sandrine; Blajman, Cesar R; Forastiere, Arlene A; Stein, Brian N; Oliner, Kelly S; Pan, Zhiying; Bach, Bruce A

Book ID
120502309
Publisher
The Lancet
Year
2013
Tongue
English
Weight
615 KB
Volume
14
Category
Article
ISSN
1470-2045

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial of cisplatin and vinore
A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
✍ Enrique Espinosa; Pilar Zamora; Alfredo Millá; Serafin Morales; Raquel Molina; M 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## Abstract ## Objective. We assessed the response rate and the toxicity of cisplatin plus vinorelbine in patients with this condition. ## Patients and Method. Forty‐two patients were included. Therapy consisted of cisplatin, 100 mg/m^2^ on day 1, and vinorelbine, 25 mg/m^2^ on days 1 and 8, giv

Paclitaxel, cisplatin, and 5-fluorouraci
Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck
✍ Maha Hussain; Shirish Gadgeel; Omer Kucuk; Wei Du; Walter Salwen; John Ensley 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 3 views

## BACKGROUND. The combination of cisplatin and 5-flurouracil (5-FU) is considered standard therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Paclitaxel has exhibited single-agent activity in patients with this disease. The authors conducted thi